Table 1. Summary of clinical trials related to HER2DX.

Trial	Clinical trials number	Intervention	Phase	Patient population	Rate of pCR	Molecular typing	Ref.
CALGB-40601	NCT00770809	Paclitaxel + trastuzumab + lapatinib or paclitaxel + trastuzumab or paclitaxel + lapatinib	III	305	THP: 56%, 95% CI: 47–65%; TH: 46%, 95% CI: 37–55%; TL: 32%, 95% CI: 22–45%	HER2+	(11)
ISPY-2	NCT01042379	T-DM1 + pertuzumab or paclitaxel + trastuzumab + pertuzumab, or a control arm of paclitaxel + trastuzumab. Doxorubicin + cyclophosphamide before surgery	II	128	T-DM1/P: 55%, 95% PI: 41–69%; THP: 56%, 95% PI: 42–70%; TH: 25%, 95% PI: 11–38%	HER2+	(11,12)
PAMELA	NCT01973660	Trastuzumab + lapatinib ± letrozole or tamoxifen	II	151	41%, 95% CI: 31–51%	HER2+	(13)
PerELISA	NCT02411344	–	–	–	–	HER2+	(14)
DAPHNe	NCT03716180	Paclitaxel + trastuzumab + pertuzumab before surgery	II	98	56.7%	HER2+	(15)
BiOnHER	NCT05912062	Trastuzumab + pertuzumab without chemotherapy followed by + trastuzumab + pertuzumab	II	49	45.6%	HER2+	(11)
NEOHER	–	Docetaxel + pertuzumab + trastuzumab ± carboplatin	–	44	THP: 66.7%; THCP: 78.6%	HER2+	(16)
GOM	–	Docetaxel + carboplatin + trastuzumab ± pertuzumab	–	155	TCH: 57%, 95% CI: 49–65%; TCHP: 61%, 95% CI: 50–71%	HER2	(11,12)
PHERGain	NCT03161353	Trastuzumab + pertuzumab+ endocrine therapy docetaxel + pertuzumab + trastuzumab + carboplatin	II	356	TCHP: 56.4%; HP: 33.8%	HER2+	(17)

CI, confidence interval; HER2⁺, human epidermal growth factor receptor 2-positive; P, pertuzumab; pCR, pathological complete response; PI, probability interval; ref., reference; TCH, docetaxel, carboplatin, and trastuzumab; TCHP, docetaxel, carboplatin, trastuzumab, and pertuzumab; TH, docetaxel-trastuzumab; THP, docetaxel, trastuzumab, and pertuzumab; TL, docetaxel-lobaplatin; T-DM1, trastuzumab emtansine.